Your browser doesn't support javascript.
loading
Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Bhatt, Vijaya Raj; Balasetti, Vamshi; Jasem, Jagar A; Giri, Smith; Armitage, James O; Loberiza, Fausto R; Bociek, R Gregory; Bierman, Philip J; Maness, Lori J; Vose, Julie M; Fayad, Pierre; Akhtari, Mojtaba.
Afiliação
  • Bhatt VR; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Balasetti V; Department of Neurology, University of Nebraska Medical Center, Omaha, NE.
  • Jasem JA; Department of Neurology, Ohio State University, Columbus, OH.
  • Giri S; Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN.
  • Armitage JO; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Loberiza FR; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Bociek RG; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Bierman PJ; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Maness LJ; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Vose JM; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Fayad P; Department of Neurology, University of Nebraska Medical Center, Omaha, NE.
  • Akhtari M; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE. Electronic address: mojtaba.akhtari@unmc.edu.
Clin Lymphoma Myeloma Leuk ; 15(10): 606-11, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26184063
ABSTRACT

BACKGROUND:

Central nervous system complications (CNSC) can be the cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to determine the incidence of CNSC and its impact on survival. PATIENTS AND

METHODS:

This retrospective cohort study included patients with hematologic disorders who received allo-HSCT between 2002 and 2011 at the University of Nebraska Medical Center.

RESULTS:

Of the 351 patients identified, 45 developed CNSC (12.8%). The 100-day cumulative incidence of CNSC was 8% (95% confidence interval, 8-15). The most common CNSC included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and infection (9%). The 5-year overall survival was significantly lower among patients with versus without CNSC (14% vs. 44%, P = .0004). In multivariate analysis, the risk of mortality for patients with versus without CNSC was significantly higher (hazard ratio, 1.56; 95% confidence interval, 1.03-2.36; P = .04).

CONCLUSION:

The occurrence of CNSC after allo-HSCT was associated with reduced survival. Identifying patients at risk, monitoring, early detection, and management of CNSC after allo-HSCT are needed to improve outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Convulsões / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Acidente Vascular Cerebral / Síndrome da Leucoencefalopatia Posterior Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Convulsões / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Acidente Vascular Cerebral / Síndrome da Leucoencefalopatia Posterior Idioma: En Ano de publicação: 2015 Tipo de documento: Article